STOCK TITAN
  1. Home
  2. News
  3. AQST

Aquestive Therapeutics Inc - AQST STOCK NEWS

Welcome to our dedicated news page for Aquestive Therapeutics (Ticker: AQST), a resource for investors and traders seeking the latest updates and insights on Aquestive Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aquestive Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aquestive Therapeutics's position in the market.

News
Aquestive Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Conference
Rhea-AI Summary
Aquestive Therapeutics, Inc. (NASDAQ: AQST) will participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13th, holding a fireside chat and investor meetings. A webcast and replay will be available on the Company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.25%
Tags
conferences
-
News
Aquestive Therapeutics Doses First Patient in Phase 3 Pivotal Clinical Study Evaluating Pharmacokinetics and Pharmacodynamics of Anaphylm™ (epinephrine) Sublingual Film
Rhea-AI Summary
Aquestive Therapeutics, Inc. (NASDAQ: AQST) has initiated its initial Phase 3 pivotal Pharmacokinetic (PK) clinical study of Anaphylm™ (epinephrine) Sublingual Film, the Company’s orally administered epinephrine prodrug product candidate for the treatment of severe life-threatening allergic reactions, including anaphylaxis. The study aims to compare the PK and pharmacodynamics (PD) of Anaphylm versus existing epinephrine injection and autoinjector products. The topline data is expected in the first quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.24%
Tags
clinical trial
-
News
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for Anaphylm™ at American College of Allergy Asthma and Immunology (ACAAI) Annual Meeting
Rhea-AI Summary
Aquestive Therapeutics, Inc. (NASDAQ: AQST) announced positive data from pharmacokinetic (PK) and pharmacodynamic (PD) pre-clinical and clinical studies of Anaphylm™ (epinephrine) Sublingual Film to be presented at the ACAAI annual meeting. The results show promising potential for the treatment of acute allergic reactions, pending FDA approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
conferences
News
Aquestive Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
Rhea-AI Summary
Aquestive Therapeutics, Inc. reported financial results for Q3 2023, with a 25% YoY growth in year-to-date revenue. They raised their full year 2023 revenue guidance to $47-$50 million and improved non-GAAP adjusted EBITDA loss guidance. Aquestive also reiterated the commencement of a pivotal PK study for Anaphylm™ (epinephrine) Sublingual Film, with topline data expected in Q1 2024. They completed debt refinancing, resulting in approximately $28 million of cash savings through June 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.91%
Tags
earnings
-
News
Aquestive Therapeutics Completes $45 Million Debt Refinancing
Rhea-AI Summary
Aquestive Therapeutics, Inc. has announced the refinancing of its existing debt facility. The company redeemed its 12.5% senior secured notes due 2025 and issued new 13.5% senior secured notes due 2028. The new financing of $45,000,000 will be used to repay all outstanding notes issued under the previous facility. The notes bear interest at a fixed rate of 13.5% per year and will mature on November 1, 2028. The financing transaction also includes royalty agreements with the note holders for the company's products Anaphylm and Libervant.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.49%
Tags
none
-
News
Aquestive Therapeutics to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 6 and Host Conference Call on November 7 at 8:00 a.m. ET
Rhea-AI Summary
Aquestive Therapeutics, Inc. will report Q3 2023 results and provide business updates on November 6, 2023. The conference call for investors will be held on November 7, 2023, at 8:00 a.m. ET. A live webcast of the call will be available on Aquestive's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.97%
Tags
conferences earnings
News
Aquestive Therapeutics Provides Business Update
Rhea-AI Summary
Aquestive Therapeutics receives positive feedback from FDA on pivotal study protocol for Anaphylm Sublingual Film and provides business update
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.75%
Tags
none
-
News
Aquestive Therapeutics Reaffirms Timeline and Pathway for Anaphylm™ (epinephrine) Sublingual Film
Rhea-AI Summary
Aquestive provides update on development timeline for oral epinephrine product candidate, Anaphylm
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.76%
Tags
none
-
News
Aquestive Therapeutics Receives FDA Acceptance of New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film in Pediatric Patients and Assignment of Prescription Drug User Fee Act (PDUFA) Date
Rhea-AI Summary
FDA accepts Aquestive's NDA for Libervant Buccal Film in pediatric patients between two and five years of age with a PDUFA goal date of April 28, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.67%
Tags
clinical trial
News
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
Rhea-AI Summary
Aquestive Therapeutics to participate in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.7%
Tags
conferences
Stock AQST logo
Aquestive Therapeutics Inc

Nasdaq:AQST

AQST Rankings

#3241 Ranked by Market Cap
#287 Ranked by Stock Gains
N/A Ranked by Dividends

AQST Stock Data

346.38M
65.02M
5.03%
34.33%
2.53%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States
Warren

About AQST

aquestive therapeutics is a specialty pharmaceutical company that advances and commercializes medicines to solve critical healthcare problems and meaningfully improve people’s lives. our team asks questions and identifies issues others have not, and builds solutions that empower patients and their caregivers with better ways to manage complex diseases. our initial focus, supported by our current approved products and late stage pipeline, is to address immediate cns challenges.